Translate Bio Granted Patent ‘MRNA therapy for Pompe disease’

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6595&f=G&l=50&d=PTXT&p=132&S1=20210817&OS=20210817&RS=20210817

byBill Haddad

August 17, 2021

1 minute read

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6595&f=G&l=50&d=PTXT&p=132&S1=20210817&OS=20210817&RS=20210817

Kiora Pharma Shares To Session High As Traders Circulate Over Last Few Mins. FDA AccessData.gov Orphan Drug Listing For Co.’s Retinitis Pigmentosa Treatment

By Benzinga Newsdesk

Today, 6:59 AM

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=868421

KPRX

Moderna PR Confirms First Participant Dosed In Phase 2 Study Of Omicron-Specific Booster Candidate And Publication Of Data On Booster Durability Against Omicron Variant

By Benzinga Newsdesk

Today, 6:59 AM

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 2 study of the Company's

MRNA

Read Why This Analyst Is Bullish On Restaurant Brands

By Shivani Kumaresan

Today, 6:59 AM

Oppenheimer analyst Brian Bittner reiterated an Outperform rating on the shares of Restaurant Brands International Inc (NYSE:QSR) with a price target of…

QSR